drugset / Trial / NCT00003522

Antineoplaston Therapy in Treating Patients With Cancer of the Small Intestine

NCT00003522

Phase 2 Terminated 1 enrolled Burzynski Research Institute
NaSingle-groupOpen-labelTreatment

Summary

Current therapies for Cancer of the Small Intestine provide very limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the treatment of Cancer of the Small Intestine. PURPOSE: This study is being performed to determine the effects (good and bad) that Antineoplaston therapy has on patients with Cancer of the Small Intestine.

Timeline

Start
1997-08-13
Primary completion
1997-12-14
Completion
1997-12-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Astugenal Unknown Intravenous
Subject antineoplaston A10 Small molecule Intravenous